657 Severe Malabsorption Associated With Olmesartan: A French Nationwide Cohort Study

Basson, Mickaël; Mezzarobba, M.; Weill, Alain; Ricordeau, P.; Allemand, H.; Alla, François; Carbonnel, Franck

doi:10.1016/s0016-5085(14)60411-x

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a recent epidemiological study performed in France has shown a significant association between hospitalisation for malabsorption and olmesartan prescription as compared with angiotensin-converting enzyme inhibitors and other sartans. 21 The lack of association between gastrointestinal events and olmesartan found in the ROADMAP trial 19 and in the paper by Padwal et al 20 could be due to the confounding effect of diabetic neuropathy, which may provoke chronic diarrhoea. In addition, the incidence of olmesartan enteropathy is low and may require large populations of patients to be clearly demonstrated.…”

Section: Discussionmentioning

confidence: 98%

“…Thirdly, as in the study by Rubio‐Tapia et al ., duodenal mucosa returned to normal after olmesartan withdrawal. In addition, a recent epidemiological study performed in France has shown a significant association between hospitalisation for malabsorption and olmesartan prescription as compared with angiotensin‐converting enzyme inhibitors and other sartans . The lack of association between gastrointestinal events and olmesartan found in the ROADMAP trial and in the paper by Padwal et al .…”

Section: Discussionmentioning

confidence: 99%

“…The median cumulative hospital stay was 29 days . Four patients required intensive care (12 days [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]). Seven patients required enteral nutrition (30 days ) and 10 required parenteral nutrition (29 days ).…”

Section: Outcomementioning

confidence: 99%

“…Three patients were hospitalised (12 days [12][13][14][15][16][17][18][19][20][21][22]), and two required intensive care. No patient received artificial nutrition, steroids or immunosuppressants.…”

Section: Outcomementioning

confidence: 99%

See 3 more Smart Citations

Olmesartan-associated enteropathy: results of a national survey

Marthey

Cadiot

Seksik

et al. 2014

Aliment Pharmacol Ther

176

171

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Outcomementioning

confidence: 99%

Section: Outcomementioning

confidence: 99%

See 2 more Smart Citations

Olmesartan-associated enteropathy: results of a national survey

Marthey

Cadiot

Seksik

et al. 2014

Aliment Pharmacol Ther

176

171

View full text Add to dashboard Cite

show abstract

“…Whether this association is limited to olmesartan or concerns the whole ARBs class is an unresolved issue. A large cohort study has shown that only olmesartan, unlike other ARBs, is associated with an increased risk of severe intestinal malabsorption resulting in hospitalization [ 13 ]. On the other hand, single cases of sprue-like enteropathy associated with other ARBs (irbesartan, valsartan, and losartan, respectively) have been reported [ 9 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

A Case of Moderate Sprue-Like Enteropathy Associated With Telmisartan

et al. 2017

View full text Add to dashboard Cite

Sprue-like enteropathy associated with olmesartan medoxomil use has been recently reported. Its clinical manifestations include diarrhea, weight loss and malabsorption. Duodenal biopsies show villous atrophy (VA) with or without intraepithelial lymphocytosis and inflammation of the lamina propria. Serology for celiac disease (CD) is negative and gluten-free diet does not result in clinical improvement. Symptoms resolve after olmesartan discontinuation. Follow-up biopsies show recovery/improvement of the duodenum. Whether sprue-like enteropathy is a specific adverse reaction to olmesartan or rather a class effect of angiotensin-receptor blockers (ARBs) remains a controversial issue. We report a case of sprue-like enteropathy associated with telmisartan. A 52-year-old man presented with chronic diarrhea, abdominal discomfort and significant weight loss. In the last 3 years, he had been treated with telmisartan 40 mg/day for hypertension after right adrenalectomy for an aldosterone-producing adenoma. Laboratory investigations showed no significant abnormalities: Hb 13.6 g/dL, serum albumin 3.9 g/dL, total cholesterol 193 mg/dL, serum creatinine 0.99 mg/dL, sodium 143.6 mmol/L, K+ 4.3 mmol/L, calcium 9.3 mg/dL, phosphorus 3.9 mg/dL and 25-OH-D3 27.7 ng/mL. Duodenal histology showed subtotal VA and inflammation of the lamina propria. CD serology was negative. HLA-DQ typing showed absence of the DQ2/DQ8 haplotypes. After telmisartan discontinuation, patient’s symptoms subsided, and his body weight increased despite persistence of a gluten-containing diet. Follow-up biopsies at 3 showed progressive duodenal recovery. Very few cases of sprue-like enteropathy associated with ARBs other than olmesartan have been reported. Our case of telmisartan-associated enteropathy further suggests that sprue-like disease may be a class effect of ARBs.

show abstract

657 Severe Malabsorption Associated With Olmesartan: A French Nationwide Cohort Study

Cited by 2 publications

References 0 publications

Olmesartan-associated enteropathy: results of a national survey

Olmesartan-associated enteropathy: results of a national survey

A Case of Moderate Sprue-Like Enteropathy Associated With Telmisartan

Contact Info

Product

Resources

About